RBC Capital Maintains Outperform on IDEAYA Biosciences, Raises Price Target to $32
Portfolio Pulse from richadhand@benzinga.com
RBC Capital analyst Gregory Renza maintains an Outperform rating on IDEAYA Biosciences (NASDAQ:IDYA) and raises the price target from $30 to $32.
August 11, 2023 | 4:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital maintains an Outperform rating on IDEAYA Biosciences and raises the price target from $30 to $32, which could positively impact the stock.
The raised price target by RBC Capital indicates a positive outlook for IDEAYA Biosciences. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100